George Bakris to Male
This is a "connection" page, showing publications George Bakris has written about Male.
Connection Strength
3.955
-
RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024 03 05; 331(9):740-749.
Score: 0.050
-
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. JAMA Cardiol. 2023 08 01; 8(8):732-741.
Score: 0.048
-
Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
Score: 0.048
-
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 05; 22(5):213-218.
Score: 0.044
-
Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. Am J Nephrol. 2021; 52(12):969-976.
Score: 0.043
-
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. Cardiovasc Diabetol. 2021 09 14; 20(1):187.
Score: 0.042
-
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021 07; 78(1):74-81.
Score: 0.041
-
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714.
Score: 0.040
-
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020 07; 76(1):144-149.
Score: 0.039
-
Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. Am J Nephrol. 2020; 51(3):249-254.
Score: 0.038
-
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
Score: 0.037
-
Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. J Fam Pract. 2019 10; 68(8):S1-S6.
Score: 0.037
-
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 04; 20(4):694-702.
Score: 0.033
-
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. Am J Med. 2018 05; 131(5):555-564.e3.
Score: 0.032
-
Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circ J. 2017 Aug 25; 81(9):1337-1345.
Score: 0.031
-
Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J. 2017 01 07; 38(2):93-100.
Score: 0.031
-
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail. 2017 06; 19(6):792-799.
Score: 0.030
-
Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J. 2016 May 25; 80(6):1404-12.
Score: 0.029
-
Hydrochlorothiazide as the Diuretic of Choice for Hypertension: Time to Kick the Habit. J Am Coll Cardiol. 2016 Feb 02; 67(4):390-391.
Score: 0.029
-
Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply. JAMA. 2016 Jan 19; 315(3):306.
Score: 0.029
-
Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7.
Score: 0.028
-
Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034.
Score: 0.028
-
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 01; 314(9):884-94.
Score: 0.028
-
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14; 314(2):151-61.
Score: 0.028
-
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015 Apr 07; 65(13):1314-1321.
Score: 0.027
-
Reply: A mechanistic explanation for the minimal impact of renal denervation on 24-h ambulatory blood pressure in SIMPLICITY HTN-3. J Am Coll Cardiol. 2015 Mar 10; 65(9):959-60.
Score: 0.027
-
Efficacy and safety of perindopril arginine + amlodipine in hypertension. J Am Soc Hypertens. 2015 Apr; 9(4):266-74.
Score: 0.027
-
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol. 2014; 40(6):572-81.
Score: 0.027
-
Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8.
Score: 0.026
-
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27.
Score: 0.026
-
In search for the 'sweet spot' for blood pressure level in diabetes. Heart. 2014 Sep 15; 100(18):1404-5.
Score: 0.026
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
Score: 0.026
-
Renal denervation for resistant hypertension. N Engl J Med. 2014 07 10; 371(2):184.
Score: 0.026
-
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014 Sep 16; 64(11):1071-8.
Score: 0.025
-
Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated? J Renin Angiotensin Aldosterone Syst. 2014 Mar; 15(1):97-8.
Score: 0.025
-
Early patterns of blood pressure change and future coronary atherosclerosis. JAMA. 2014 Feb 05; 311(5):471-2.
Score: 0.025
-
Orthostatic hypotension associated with baroreceptor dysfunction: treatment approaches. J Clin Hypertens (Greenwich). 2014 Feb; 16(2):141-8.
Score: 0.025
-
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus. Hypertension. 2014 Feb; 63(2):220-1.
Score: 0.025
-
Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014 May 13; 63(18):1924-5.
Score: 0.025
-
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013 Oct; 8(10):1694-701.
Score: 0.024
-
Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience. J Hypertens. 2013 Aug; 31(8):1537-8.
Score: 0.024
-
The author replies. Kidney Int. 2013 Jul; 84(1):215.
Score: 0.024
-
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich). 2013 Jul; 15(7):473-9.
Score: 0.024
-
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013 Jul 15; 112(2):255-9.
Score: 0.024
-
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013 Aug; 27(8):479-86.
Score: 0.023
-
The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney Int. 2013 Jan; 83(1):20-2.
Score: 0.023
-
Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013 Feb; 15(2):92-100.
Score: 0.023
-
Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012 Dec; 125(12):1229.e1-1229.e10.
Score: 0.023
-
Chronic kidney disease: a coronary heart disease equivalent? Lancet. 2012 Sep 01; 380(9844):783-5.
Score: 0.022
-
Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease? J Hypertens. 2012 Mar; 30(3):466-7.
Score: 0.022
-
Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr; 6(2):152-8.
Score: 0.022
-
A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique? J Hypertens. 2012 Jan; 30(1):48-50.
Score: 0.022
-
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes Obes Metab. 2012 Feb; 14(2):181-6.
Score: 0.021
-
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011 Feb; 13(2):81-8.
Score: 0.020
-
Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83.
Score: 0.020
-
Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010 Nov-Dec; 4(6):302-10.
Score: 0.020
-
Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov; 56(5):824-30.
Score: 0.020
-
Lower blood pressure goals in high-risk cardiovascular patients: are they defensible? Cardiol Clin. 2010 Aug; 28(3):447-52.
Score: 0.020
-
Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):678-86.
Score: 0.019
-
Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14.
Score: 0.019
-
Pediatrics: Masked hypertension: a risk factor in children with CKD. Nat Rev Nephrol. 2010 Mar; 6(3):132-4.
Score: 0.019
-
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
Score: 0.019
-
Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease. Semin Nephrol. 2010 Jan; 30(1):66-73.
Score: 0.019
-
Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009; 30(5):418-24.
Score: 0.018
-
Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
Score: 0.018
-
Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S3-10.
Score: 0.018
-
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens (Greenwich). 2009 Mar; 11(3):144-7.
Score: 0.018
-
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Blood Purif. 2009; 27(2):231-4.
Score: 0.018
-
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008 Aug; 74(3):364-9.
Score: 0.017
-
Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40.
Score: 0.017
-
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008 Jun; 73(11):1303-9.
Score: 0.017
-
Comparative efficacy of two different beta-blockers on 24-hour blood pressure control. J Clin Hypertens (Greenwich). 2008 Feb; 10(2):112-8.
Score: 0.016
-
Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study. J Cardiometab Syndr. 2008; 3(1):18-25.
Score: 0.016
-
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr. 2008; 3(4):229-33.
Score: 0.016
-
A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol. 2008; 28(2):324-9.
Score: 0.016
-
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 2007 Oct; 72(7):879-85.
Score: 0.016
-
Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007 Jun; 7(3):191-9.
Score: 0.016
-
Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens. 2007 Sep; 21(9):709-16.
Score: 0.016
-
Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot study. J Hum Hypertens. 2007 May; 21(5):347-52.
Score: 0.015
-
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers. Am J Cardiovasc Drugs. 2007; 7 Suppl 1:25-9.
Score: 0.015
-
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec; 29(12):2592-7.
Score: 0.015
-
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55.
Score: 0.015
-
The continuum of blood pressure risk: when is the best time to intervene? Curr Hypertens Rep. 2006 Oct; 8(5):395-7.
Score: 0.015
-
Controlled-release carvedilol in the treatment of essential hypertension. Am J Cardiol. 2006 Oct 02; 98(7A):32L-38L.
Score: 0.015
-
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep. 2006 Jun; 6(3):219-24.
Score: 0.015
-
Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. J Hum Hypertens. 2006 Sep; 20(9):693-700.
Score: 0.015
-
Albuminuria and cardiovascular risk. Heart Fail Clin. 2006 Jan; 2(1):53-9.
Score: 0.014
-
Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach. J Cardiometab Syndr. 2006; 1(5):334-42; quiz 343.
Score: 0.014
-
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005 Dec; 46(6):1309-15.
Score: 0.014
-
Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):587-95; quiz 596-7.
Score: 0.014
-
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study. Am J Nephrol. 2005 Jul-Aug; 25(4):393-9.
Score: 0.014
-
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
Score: 0.014
-
The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. J Diabetes Complications. 2005 Mar-Apr; 19(2):74-9.
Score: 0.013
-
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
Score: 0.013
-
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes. Prev Cardiol. 2005; 8(2):87-92.
Score: 0.013
-
beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004 Dec 13-27; 164(22):2465-71.
Score: 0.013
-
Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6.
Score: 0.013
-
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension. 2004 Nov; 44(5):637-42.
Score: 0.013
-
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):437-42; quiz 443-4.
Score: 0.013
-
Hypertension control rates: time for translation of guidelines into clinical practice. Am J Med. 2004 Jul 01; 117(1):62-4.
Score: 0.013
-
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Am J Hypertens. 2004 Jul; 17(7):590-6.
Score: 0.013
-
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19; 14(3):e076444.
Score: 0.013
-
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7.
Score: 0.012
-
What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207.
Score: 0.012
-
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes Obes Metab. 2024 Jan; 26(1):191-200.
Score: 0.012
-
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65.
Score: 0.012
-
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab. 2023 08; 25(8):2151-2162.
Score: 0.012
-
Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich). 2003 May-Jun; 5(3):202-9.
Score: 0.012
-
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1.
Score: 0.012
-
Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12.
Score: 0.012
-
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov; 20(11):2257-67.
Score: 0.011
-
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.
Score: 0.011
-
Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goals. Postgrad Med. 2002 Oct; 112(4):73-4, 77-80, 83-4.
Score: 0.011
-
Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416.
Score: 0.011
-
Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2002 Jul-Aug; 4(4 Suppl 1):26-31.
Score: 0.011
-
Evaluation and treatment of patients with systemic hypertension. Circulation. 2002 May 28; 105(21):2458-61.
Score: 0.011
-
Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review. JAMA Cardiol. 2022 05 01; 7(5):549-555.
Score: 0.011
-
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care. 2022 04 01; 45(4):888-897.
Score: 0.011
-
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens. 2002 Mar; 16(3):185-91.
Score: 0.011
-
Treatment of Resistant Hypertension With Endovascular Baroreflex Amplification: 3-Year Results From the CALM-FIM Study. JACC Cardiovasc Interv. 2022 02 14; 15(3):321-332.
Score: 0.011
-
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 03; 17(3):361-373.
Score: 0.011
-
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58.
Score: 0.011
-
Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47.
Score: 0.011
-
A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens. 2002 Jan; 15(1 Pt 1):53-7.
Score: 0.011
-
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585.
Score: 0.011
-
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 02 08; 145(6):437-447.
Score: 0.011
-
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237.
Score: 0.011
-
Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. J Am Heart Assoc. 2021 11 16; 10(22):e022479.
Score: 0.011
-
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. J Am Soc Nephrol. 2021 11; 32(11):2900-2911.
Score: 0.011
-
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 12 09; 385(24):2252-2263.
Score: 0.011
-
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 07 13; 78(2):142-152.
Score: 0.010
-
Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol. 2021 Oct; 110(10):1612-1624.
Score: 0.010
-
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.
Score: 0.010
-
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Circulation. 2021 05 04; 143(18):1735-1749.
Score: 0.010
-
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638.
Score: 0.010
-
Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich). 2001 Jan-Feb; 3(1):16-21.
Score: 0.010
-
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148.
Score: 0.010
-
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 12 31; 16(1):59-69.
Score: 0.010
-
U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. J Am Coll Cardiol. 2020 12 15; 76(24):2907-2910.
Score: 0.010
-
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation. 2021 02 09; 143(6):540-552.
Score: 0.010
-
Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. Am J Hypertens. 2020 11 03; 33(11):1003-1010.
Score: 0.010
-
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000 Nov; 58(5):2084-92.
Score: 0.010
-
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020 11; 8(11):903-914.
Score: 0.010
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 03; 383(23):2219-2229.
Score: 0.010
-
Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2021 Jul; 110(7):1006-1019.
Score: 0.010
-
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020 11; 229:40-51.
Score: 0.010
-
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
Score: 0.010
-
Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797.
Score: 0.009
-
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452.
Score: 0.009
-
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410.
Score: 0.009
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356.
Score: 0.009
-
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 08 27; 140(9):739-750.
Score: 0.009
-
Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int. 1999 Jul; 56(1):206-10.
Score: 0.009
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
Score: 0.009
-
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
Score: 0.009
-
The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrol Dial Transplant. 2019 03 01; 34(3):515-523.
Score: 0.009
-
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):925-933.
Score: 0.009
-
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). Am J Cardiol. 2019 02 01; 123(3):382-391.
Score: 0.009
-
Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114.
Score: 0.009
-
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550.
Score: 0.009
-
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998 Oct; 54(4):1283-9.
Score: 0.009
-
Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998 Sep; 54(3):889-96.
Score: 0.009
-
Risks for renal involvement in diabetes. Postgrad Med. 1998 Sep; 104(3):33.
Score: 0.009
-
The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. J Hum Hypertens. 1998 Sep; 12(9):653-5.
Score: 0.009
-
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018 11 01; 122(9):1496-1505.
Score: 0.009
-
Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11).
Score: 0.008
-
Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab. 2018 08; 20(8):1829-1835.
Score: 0.008
-
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 04; 36(4):947-956.
Score: 0.008
-
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
Score: 0.008
-
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018 06; 71(6):851-865.
Score: 0.008
-
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47.
Score: 0.008
-
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 03 07; 13(3):398-405.
Score: 0.008
-
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
Score: 0.008
-
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659.
Score: 0.008
-
Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5.
Score: 0.008
-
Calcium antagonism abolishes the antipressor action of vasopressin (V1) receptor antagonism. Am J Hypertens. 1997 Oct; 10(10 Pt 1):1153-8.
Score: 0.008
-
High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017 Oct; 192:76-84.
Score: 0.008
-
Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. J Clin Hypertens (Greenwich). 2017 Jul; 19(7):695-701.
Score: 0.008
-
Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801.
Score: 0.008
-
Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997 May; 15(5):545-50.
Score: 0.008
-
Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up. Hypertension. 2017 May; 69(5):836-843.
Score: 0.008
-
Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension. 1997 Mar; 29(3):744-50.
Score: 0.008
-
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921.
Score: 0.008
-
Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671.
Score: 0.008
-
On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. Hypertension. 2017 02; 69(2):220-227.
Score: 0.008
-
An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2017 02; 11(2):81-91.
Score: 0.008
-
Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996 Nov; 50(5):1641-50.
Score: 0.008
-
Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072.
Score: 0.008
-
Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072.
Score: 0.008
-
Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072.
Score: 0.008
-
Massachusetts Healthcare Reform and Trends in Emergent Colon Resection. Dis Colon Rectum. 2016 Nov; 59(11):1063-1072.
Score: 0.008
-
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310.
Score: 0.008
-
BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol. 2017 02; 28(2):671-677.
Score: 0.007
-
Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med. 1996 Aug 01; 125(3):201-4.
Score: 0.007
-
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
Score: 0.007
-
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 09; 90(3):696-704.
Score: 0.007
-
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73.
Score: 0.007
-
Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016 Apr; 34(4):788-97.
Score: 0.007
-
Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr; 18(4):299-307.
Score: 0.007
-
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
Score: 0.007
-
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996 Mar; 36(3):274-9.
Score: 0.007
-
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27.
Score: 0.007
-
Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis. 2015 Dec; 243(2):553-9.
Score: 0.007
-
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct; 17(10):1057-65.
Score: 0.007
-
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens. 2015 Nov; 9(11):845-54.
Score: 0.007
-
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779.
Score: 0.007
-
New agents for hyperkalemia. N Engl J Med. 2015 04 16; 372(16):1570-1.
Score: 0.007
-
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76.
Score: 0.007
-
Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. J Am Soc Nephrol. 1995 Mar; 5(9):1684-8.
Score: 0.007
-
Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. J Am Soc Hypertens. 2015 Apr; 9(4):299-306.
Score: 0.007
-
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49.
Score: 0.007
-
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15; 372(3):211-21.
Score: 0.007
-
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J Card Fail. 2014 Dec; 20(12):953-8.
Score: 0.007
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
Score: 0.006
-
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol. 2014; 39(6):499-508.
Score: 0.006
-
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014 Apr; 19(2):90-7.
Score: 0.006
-
A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10; 370(15):1393-401.
Score: 0.006
-
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. Clin Pharmacol Ther. 2014 Jul; 96(1):27-35.
Score: 0.006
-
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014 Mar; 32(3):635-43.
Score: 0.006
-
Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014 Feb; 32(2):415-22.
Score: 0.006
-
Association of cognitive dysfunction with cardiovascular disease events in elderly hypertensive patients. J Hypertens. 2014 Feb; 32(2):423-31.
Score: 0.006
-
ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications. 1994 Jan-Mar; 8(1):2-6.
Score: 0.006
-
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014 Jan; 7(1):51-8.
Score: 0.006
-
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 12 26; 369(26):2492-503.
Score: 0.006
-
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant. 2013 Nov; 28(11):2841-50.
Score: 0.006
-
Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens. 2014 Feb; 8(2):103-16.
Score: 0.006
-
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1135-44.
Score: 0.006
-
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35.
Score: 0.006
-
Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly. Am J Nephrol. 2013; 38(3):195-203.
Score: 0.006
-
Obesity, blood pressure, and cardiovascular outcomes - Authors' reply. Lancet. 2013 Jun 08; 381(9882):1982-3.
Score: 0.006
-
Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8.
Score: 0.006
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73.
Score: 0.006
-
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 Jun; 126(6):501-8.
Score: 0.006
-
Evaluating the role of key learning theories in ECHO: a telehealth educational program for primary care providers. Prog Community Health Partnersh. 2013; 7(4):361-8.
Score: 0.006
-
Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013 Mar; 61(3):404-12.
Score: 0.006
-
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16; 381(9866):537-45.
Score: 0.006
-
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease. Hypertension. 2013 Jan; 61(1):82-8.
Score: 0.006
-
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013 Apr; 34(16):1204-14.
Score: 0.006
-
Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug; 60(2):310-8.
Score: 0.006
-
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med. 2012 Jul; 125(7):661-9.
Score: 0.006
-
Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992 Apr; 41(4):912-9.
Score: 0.005
-
Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich). 2012 May; 14(5):284-92.
Score: 0.005
-
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012 Mar; 34(3):537-51.
Score: 0.005
-
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012 Apr; 125(4):399-410.
Score: 0.005
-
Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7.
Score: 0.005
-
Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
Score: 0.005
-
Using an established telehealth model to train urban primary care providers on hypertension management. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):45-50.
Score: 0.005
-
Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011 Nov; 58(5):895-901.
Score: 0.005
-
Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis. 2011 Dec; 58(6):886-93.
Score: 0.005
-
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1.
Score: 0.005
-
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Press. 2012 Apr; 21(2):82-7.
Score: 0.005
-
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 09; 58(7):765-73.
Score: 0.005
-
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011 Jul; 13(7):467-72.
Score: 0.005
-
Effects of naproxcinod on blood pressure in patients with osteoarthritis. Am J Cardiol. 2011 May 01; 107(9):1338-45.
Score: 0.005
-
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31.
Score: 0.005
-
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16.
Score: 0.005
-
Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar; 57(3):413-20.
Score: 0.005
-
Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9.
Score: 0.005
-
Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 Dec 15; 113(12):987-8.
Score: 0.005
-
Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Intern Med J. 2010 Dec; 40(12):833-41.
Score: 0.005
-
Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol. 2010 Dec; 21(12):2131-42.
Score: 0.005
-
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.
Score: 0.005
-
Predictors of hypertension control in a diverse general cardiology practice. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):570-7.
Score: 0.005
-
Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med. 1990 Jul 12; 323(2):86-90.
Score: 0.005
-
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010 Jul 07; 304(1):61-8.
Score: 0.005
-
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29; 56(1):77-85.
Score: 0.005
-
Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 May 01; 112(9):707-8.
Score: 0.005
-
Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology. 1990 Apr; 175(1):57-60.
Score: 0.005
-
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010 May 05; 102(9):596-604.
Score: 0.005
-
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S23-33.
Score: 0.005
-
The effects of enalapril on urinary protein excretion in patients with idiopathic membranous nephropathy. J Clin Pharmacol. 1990 Feb; 30(2):155-8.
Score: 0.005
-
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010 Mar; 3(2):253-60.
Score: 0.005
-
Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990 Jan; 258(1 Pt 2):F115-20.
Score: 0.005
-
Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):51-8.
Score: 0.005
-
Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):22-31.
Score: 0.005
-
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010; 31(2):95-103.
Score: 0.005
-
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism. 2010 Mar; 59(3):385-9.
Score: 0.005
-
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009 Sep 28; 169(17):1587-94.
Score: 0.005
-
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24; 374(9699):1423-31.
Score: 0.005
-
Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol. 2010 Oct 29; 144(3):383-8.
Score: 0.005
-
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol. 2010 Jul 23; 142(3):279-87.
Score: 0.004
-
Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int J Cardiol. 2010 May 28; 141(2):167-74.
Score: 0.004
-
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens. 2009 Mar; 22(3):332-8.
Score: 0.004
-
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04; 359(23):2417-28.
Score: 0.004
-
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 Oct 14; 118(16):1643-50.
Score: 0.004
-
A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol. 2009 Sep 11; 137(1):1-8.
Score: 0.004
-
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009 Mar; 11(3):234-8.
Score: 0.004
-
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008 Aug; 156(2):277-83.
Score: 0.004
-
A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure. Am J Cardiol. 2008 Jun 15; 101(12):1772-6.
Score: 0.004
-
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S46-55.
Score: 0.004
-
N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK). Circulation. 2008 Apr 01; 117(13):1685-92.
Score: 0.004
-
Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8.
Score: 0.004
-
Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man. Miner Electrolyte Metab. 1988; 14(6):343-6.
Score: 0.004
-
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008 Jan-Feb; 17(1):27-36.
Score: 0.004
-
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press. 2008; 17(1):7-17.
Score: 0.004
-
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr. 2008; 3(4):211-7.
Score: 0.004
-
Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
Score: 0.004
-
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007 Nov; 9(11):842-9.
Score: 0.004
-
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007 Oct; 25(10):2082-92.
Score: 0.004
-
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007 Oct; 9(10):760-9.
Score: 0.004
-
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007 Aug; 50(2):299-305.
Score: 0.004
-
Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007 Jul; 120(7):610-5.
Score: 0.004
-
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007 Jun 11; 167(11):1122-9.
Score: 0.004
-
beta-blocker use and diabetes symptom score: results from the GEMINI study. Diabetes Obes Metab. 2007 May; 9(3):408-17.
Score: 0.004
-
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May; 9(5):355-64.
Score: 0.004
-
Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med. 2007 Jul; 24(7):759-63.
Score: 0.004
-
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007; 16(1):13-9.
Score: 0.004
-
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8.
Score: 0.004
-
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):840-9.
Score: 0.004
-
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 Jan; 71(1):31-8.
Score: 0.004
-
The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol. Circulation. 1986 Nov; 74(5):1061-5.
Score: 0.004
-
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol. 2006 Oct 01; 98(7):890-4.
Score: 0.004
-
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. J Clin Hypertens (Greenwich). 2006 Aug; 8(8):571-81; quiz 582-3.
Score: 0.004
-
Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
Score: 0.004
-
An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2006 Apr; 8(4):241-50; quiz 251-2.
Score: 0.004
-
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006 Apr; 98(4):618-26.
Score: 0.004
-
Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006 Jan; 151(1):176-84.
Score: 0.004
-
The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005 Nov; 28(11):2686-90.
Score: 0.004
-
The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005 Oct; 7(10):578-86.
Score: 0.003
-
Association of NEDD4L ubiquitin ligase with essential hypertension. Hypertension. 2005 Sep; 46(3):488-91.
Score: 0.003
-
Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit. 2005 Jun; 10(3):157-63.
Score: 0.003
-
Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005 Apr; 67(4):1483-8.
Score: 0.003
-
A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985 Feb; 27(2):465-8.
Score: 0.003
-
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich). 2005 Feb; 7(2):73-80.
Score: 0.003
-
Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study. J Hypertens. 2004 Jan; 22(1):217-22.
Score: 0.003
-
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 03; 290(21):2805-16.
Score: 0.003
-
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6):1206-52.
Score: 0.003
-
Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2003 Sep-Oct; 5(5):322-9.
Score: 0.003
-
Pulmonary scar carcinoma. A clinicopathologic analysis. Cancer. 1983 Aug 01; 52(3):493-7.
Score: 0.003
-
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
Score: 0.003
-
The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
Score: 0.003
-
Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. 2003 Jun; 41(6):1267-77.
Score: 0.003
-
Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun; 16(6):460-6.
Score: 0.003
-
Disopyramide-associated liver dysfunction. Mayo Clin Proc. 1983 Apr; 58(4):265-7.
Score: 0.003
-
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
Score: 0.003
-
Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome. Postgrad Med. 2002 Oct; 112(4):24-6, 29-30, 33-4 passim.
Score: 0.003
-
The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clin Proc. 1982 Oct; 57(10):657-60.
Score: 0.003
-
Roundtable discussion: problems in the management of hypertension. J Clin Hypertens (Greenwich). 2002 May-Jun; 4(3):207-13.
Score: 0.003
-
Psychogenic vertigo: a review. Postgrad Med. 1981 Nov; 70(5):69-71, 74, 77.
Score: 0.003
-
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28.
Score: 0.003
-
Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001 May; 37(5):1268-72.
Score: 0.003
-
Lithium prophylaxis and the kidney. J Affect Disord. 1981 Mar; 3(1):37-42.
Score: 0.003
-
Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 Apr; 57(4):1651-61.
Score: 0.002
-
Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000 Feb 28; 160(4):481-90.
Score: 0.002
-
Dermatologic manifestations of lithium: a review. Int J Psychiatry Med. 1980-1981; 10(4):327-31.
Score: 0.002
-
Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int. 1999 May; 55(5):1849-60.
Score: 0.002
-
Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. J Clin Pharmacol. 1990 May; 30(5):468-75.
Score: 0.001
-
Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987 Oct; 110(4):406-11.
Score: 0.001